Angiogenesis inhibitors target tumor and stromal cells hampering the expression of pro-angiogenic factors such as EGF, VEGF, and their receptors (EGFR, VEGFR), or interfering with the mammalian target of rapamycin (mTOR) signaling pathway. The gene discussed is KDR; the disease is neoplasm.